Peptide Comparison
Retatrutide vs CagriSema
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Retatrutide and CagriSema share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3). On the catalogued data layer Retatrutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Retatrutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Retatrutide | CagriSema | |
|---|---|---|
| Class | GIP/GLP-1/glucagon triple agonist | Amylin + GLP-1 combination |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects | Dual amylin + GLP-1 receptor agonism |
| Route | SC injection | SC injection |
| Half-life | ~6 days | ~7 days |
| Dosage (research) | 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) | 2.4 mg / 2.4 mg SC weekly |
| Evidence tier | Phase 3 | Phase 3 |
| Research depth | 217 indexed | 113 indexed |
| Availability | Investigational | Investigational |
| Reported risks | GI side effects; Phase 3 ongoing; long-term safety unknown | GI effects; Phase 3 REDEFINE mixed results |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Retatrutide or CagriSema?
Retatrutide and CagriSema share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3). On the catalogued data layer Retatrutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Retatrutide's evidence base is currently denser.
What is the difference between Retatrutide and CagriSema?
Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; CagriSema is classed as Amylin + GLP-1 combination. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; CagriSema, Dual amylin + GLP-1 receptor agonism. Reported half-life: Retatrutide, ~6 days; CagriSema, ~7 days. Routes in published studies: Retatrutide, SC injection; CagriSema, SC injection.
Which has stronger evidence, Retatrutide or CagriSema?
Retatrutide and CagriSema sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies.
Which is more accessible, Retatrutide or CagriSema?
Neither Retatrutide nor CagriSema is an FDA-approved drug. Catalog status: Retatrutide, Investigational; CagriSema, Investigational.
Are Retatrutide and CagriSema ever combined?
Retatrutide and CagriSema appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…